ProShare Advisors’s Theriva Biologics TOVX Stock Holding History

ProShare Advisors’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1	Closed	-$7K	–	1516
2017 Q1	$7K	Sell	1 -1	-50%	-$6.98K	﹤0.01%	1556
2016 Q4	$12K	Buy	+2	New	+$20.5K	﹤0.01%	1739

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

ProShare Advisors's TOVX Position: Q2 2017 in Review

ProShare Advisors sold out of Theriva Biologics (TOVX) in Q2 2017, closing a stake of 1 share — an estimated $7K sold.

ProShare Advisors first reported a position in TOVX in Q4 2016 and held it in 2 quarters. The position peaked at $12K in Q4 2016. 53 funds tracked by Wall St. Rank hold TOVX as of Q2 2017.

ProShare Advisors reported no remaining Theriva Biologics position as of Q2 2017 after selling out during the quarter.
ProShare Advisors sold 1 Theriva Biologics share in Q2 2017, an estimated $7K.
ProShare Advisors first reported a position in Theriva Biologics in Q4 2016 and held it in 2 quarters.
ProShare Advisors's Theriva Biologics position peaked at $12K in Q4 2016.
53 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2017.

Based on ProShare Advisors's 13F filing for Q2 2017, filed 11 Aug 2017.